ERBB2 and neoplasm: The first generation of anti-cancer mAbs were those which target the tumour cells directly by binding to surface antigens, including rituximab (anti-CD20), trastuzumab (anti-human epidermal growth factor receptor-2; HER-2) and cetuximab (anti-epidermal growth factor receptor; EGFR).